About Hepatitis B Vaccines
Hepatitis B is an inflammatory condition that occurs due to infection by hepatitis B virus. Hepatitis B virus is an enveloped virus that belongs to the family of hepadnavirus. It contains a circular genome with partially double-stranded DNA. The virus interferes with the normal functioning of the liver cells. Following the viral infection, the immune system is activated against virus and hepatocytes infected with viruses. This, in turn, leads to the inflammation of the liver. Extra-hepatic manifestations of hepatitis B include polyarteritis nodosa, Gianotti-Crosti syndrome, transient serum sickness-like syndrome, and membranous glomerulonephritis. Perinatal transmission of hepatitis B virus is the most common mode of infection spread. Age of a person at the time of infection and infecting dose of virus are important factors that determine the severity of acute or chronic hepatitis B. Most of the patients suffering from acute hepatitis B recover spontaneously without significant consequences. The chronic form of infection, in some cases, can progress up to cirrhosis and liver cancer. Hepatitis B infection can be prevented by immunization with hepatitis B vaccines.
TechNavio's analysts forecast the Global Hepatitis B Vaccines market to grow at a CAGR of 4.00 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Hepatitis B Vaccines market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various vaccines intended for active immunization against different serogroups of hepatitis B virus. In terms of composition, the Global Hepatitis B Vaccines market can be segmented into the following: Mono Vaccines and Combination Vaccines.
TechNavio's report, the Global Hepatitis B Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Hepatitis B Vaccines market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• GlaxoSmithKline
• Merck
• Sanofi Pasteur
Other Prominent Vendors
• Dynavax Technologies
• Janssen Pharmaceuticals
• LG Life Sciences
• Kaketsuken
• Shenzhen Kangtai Biological Products
Market Driver
• Increased Awareness about Hepatitis B Infection and Prevention
• For a full, detailed list, view our report
Market Challenge
• Inadequate Vaccine Coverage
• For a full, detailed list, view our report
Market Trend
• Combination Vaccines
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Disease Overview
05.1 Hepatitis B: Acute and Chronic Infection
05.2 Hepatitis B: Geographical Distribution
05.3 Hepatitis B: Estimated National Immunization Coverage
05.3.1 Hepatitis B Birth Dose Vaccine
05.3.2 Third Dose of Hepatitis B Vaccine
05.4 Chronic Disease Prone Individuals for Hepatitis B
05.5 Hepatitis B: Diagnosis
05.5.1 Serological Markers
05.5.2 Hepatitis B Serologic Test Interpretation
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Composition
08.1 Mono Vaccines
08.2 Combination Vaccines
09. Market Segmentation by End-user Age Group
09.1 Global Adult Hepatitis B Vaccines Market
09.1.1 Market Size and Forecast
09.1.2 Geographical Segmentation
09.2 Global Pediatric Hepatitis B Vaccines Market
09.2.1 Market Size and Forecast
10. Geographical Segmentation
10.1 Global Hepatitis B Vaccines Market in the Americas
10.1.1 Market Size and Forecast
10.2 Global Hepatitis B Vaccines Market in the EMEA Region
10.2.1 Market Size and Forecast
10.3 Global Hepatitis B Vaccines Market in the APAC Region
10.3.1 Market Size and Forecast
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.2.1 GlaxoSmithKline
18.2.2 Sanofi Pasteur
18.2.3 Merck
18.3 Other Prominent Vendors and Future Players
19. Late-stage Pipeline Candidates
19.1 Key Information for Late-stage Pipeline Candidates
19.1.1 PR5I
19.1.2 Heplisav-B
20. Key Vendor Analysis
20.1 GlaxoSmithKline
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Business Segmentation
20.1.4 Business Segmentation by Revenue 2012 and 2013
20.1.5 Sales by Geography
20.1.6 Pipeline Products
20.1.7 Business Strategy
20.1.8 Key Information
20.1.9 SWOT Analysis
20.2 Merck
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation by Revenue 2013
20.2.4 Business Segmentation by Revenue 2012 and 2013
20.2.5 Sales by Geography
20.2.6 Business Strategy
20.2.7 Key Developments
20.2.8 SWOT Analysis
20.3 Sanofi Pasteur
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Strategy
20.3.4 Recent Developments
20.3.5 SWOT Analysis
21. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Pathway of Hepatitis B Progression
Exhibit 3: Number of Hepatitis B Birth Doses Administered in WHO Regions
Exhibit 4: Trend of Hepatitis B Birth Doses Administered in WHO Regions 2000-2013
Exhibit 5: Percentage Share of Different Regions in 2013
Exhibit 6: Number of Third Doses of Hepatitis B Administered in WHO Regions
Exhibit 7: Trend of Third Doses of Hepatitis B Administered in WHO Regions 2000-2013
Exhibit 8: Percentage Share of Different Regions in 2013
Exhibit 9: Comparison of Third Dose and Birth Dose in 2013 in WHO Regions
Exhibit 10: Disease Progression of Hepatitis B
Exhibit 11: Significance of Serological Markers
Exhibit 12: Interpretation of Serological Markers
Exhibit 13: Global Hepatitis B Vaccines Market 2013-2018 (US$ million)
Exhibit 14: Global Hepatitis B Vaccines Market Segmentation by Composition
Exhibit 15: Dosage Regimen of Engerix-B
Exhibit 16: Dosage Regimen of Fendrix
Exhibit 17: Dosage Regimen of Recombivax HB
Exhibit 18: Dosage Regimen of Infanrix hexa
Exhibit 19: Dosage Regimen of Hexacima/Hexyon
Exhibit 20: Dosage Regimen of Twinrix
Exhibit 21: Dosage Regimen of Ambirix
Exhibit 22: Dosage Regimen of Comvax
Exhibit 23: Global Hepatitis B Vaccines Market Segmentation by End-user Age Group
Exhibit 24: Global Hepatitis B Vaccines Market Segmentation by End-user Age Group 2013
Exhibit 25: Global Hepatitis B Vaccines Market Segmentation by End-user Age Group 2013-2018 (US$ million)
Exhibit 26: Global Hepatitis B Vaccines Market Segmentation by End-user Age Group 2013-2018
Exhibit 27: Global Adult Hepatitis B Vaccines Market 2013-2018 (US$ million)
Exhibit 28: Global Adult Hepatitis B Vaccines Market by Geography Segmentation
Exhibit 29: Global Pediatric Hepatitis B Vaccines Market 2013-2018 (US$ million)
Exhibit 30: Global Hepatitis B Vaccines Market by Geographical Segmentation 2013
Exhibit 31: Global Hepatitis B Vaccines Market by Geographical Segmentation 2018
Exhibit 32: Global Hepatitis B Vaccines Market by Geographical Segmentation 2013-2018 (US$ million)
Exhibit 33: Global Hepatitis B Vaccines Market by Geographical Segmentation 2013-2018
Exhibit 34: Hepatitis B Vaccines Market in the Americas 2013-2018 (US$ million)
Exhibit 35: Hepatitis B Vaccines Market in the EMEA Region 2013-2018 (US$ million)
Exhibit 36: Hepatitis B Vaccines Market in the APAC Region 2013-2018 (US$ million)
Exhibit 37: Territories with Moderate to High Risk of Developing Hepatitis B Infection
Exhibit 38: Benefits of Combination Vaccines
Exhibit 39: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 40: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 41: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 42: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 43: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 44: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 45: Merck & Co. Inc.: Sales by Geography 2013
